Cell Surface Chondroitin Sulfate Glycosaminoglycan in Melanoma: Role in the Activation of Pro-MMP-2 (pro-gelatinase A)
Overview
Authors
Affiliations
We previously reported that CS (chondroitin sulfate) GAG (glycosaminoglycan), expressed on MCSP (melanoma-specific CS proteoglycan), is important for regulating MT3-MMP [membrane-type 3 MMP (matrix metalloproteinase)]-mediated human melanoma invasion and gelatinolytic activity in vitro. In the present study, we sought to determine if CS can directly enhance MT3-MMP-mediated activation of pro-MMP-2. Co-immunoprecipitation studies suggest that MCSP forms a complex with MT3-MMP and MMP-2 on melanoma cell surface. When melanoma cells were treated with betaDX (p-nitro-beta-D-xylopyranoside) to inhibit coupling of CS on the core protein, both active form and proform of MMP-2 were no longer co-immunoprecipitated with either MCSP or MT3-MMP, suggesting a model in which CS directly binds to MMP-2 and presents the gelatinase to MT3-MMP to be activated. By using recombinant proteins, we determined that MT3-MMP directly activates pro-MMP-2 and that this activation requires the interaction of the C-terminal domain of pro-MMP-2 with MT3-MMP. Activation of pro-MMP-2 by suboptimal concentrations of MT3-MMP is also significantly enhanced in the presence of excess C4S (chondroitin 4-sulfate), whereas C6S (chondroitin 6-sulfate) or low-molecular-mass hyaluronan was ineffective. Affinity chromatography studies using CS isolated from aggrecan indicate that the catalytic domain of MT3-MMP and the C-terminal domain of MMP-2 directly bind to the GAG. Thus the direct binding of pro-MMP-2 with CS through the C-domain would present the catalytic domain of pro-MMP-2 to MT3-MMP, which facilitates the generation of the active form of MMP-2. These results suggest that C4S, which is expressed on tumour cell surface, can function to bind to pro-MMP-2 and facilitate its activation by MT3-MMP-expressing tumour cells to enhance invasion and metastasis.
Decellularized extracellular matrix-based disease models for drug screening.
Chen Z, Wang J, Kankala R, Jiang M, Long L, Li W Mater Today Bio. 2024; 29:101280.
PMID: 39399243 PMC: 11470555. DOI: 10.1016/j.mtbio.2024.101280.
Macaulay A, Yang J, Price M, Forster C, Riddle M, Ebens C Br J Dermatol. 2024; 192(1):104-117.
PMID: 39018437 PMC: 11663483. DOI: 10.1093/bjd/ljae295.
Al-Husinat L, Azzam S, Al Sharie S, Al Sharie A, Battaglini D, Robba C Crit Care. 2024; 28(1):165.
PMID: 38750543 PMC: 11094887. DOI: 10.1186/s13054-024-04942-y.
CHST11-modified chondroitin 4-sulfate as a potential therapeutic target for glioblastoma.
Lin Y, Chu Y, Liao W, Chen C, Hsiao W, Ho Y Am J Cancer Res. 2023; 13(7):2998-3012.
PMID: 37559985 PMC: 10408464.
Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma.
Markl F, Benmebarek M, Keyl J, Cadilha B, Geiger M, Karches C J Immunother Cancer. 2023; 11(5).
PMID: 37208128 PMC: 10201273. DOI: 10.1136/jitc-2022-006436.